RxDoctor Payments Data

Hilary Long, PA

Physician Assistant · Scottsdale, AZNPI 1255756219

Payments from drug & device makers

$7,221in general payments, 2019–2025

Across 191 payments — averaging $37.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dendreon Pharmaceuticals LLC$1K
  • Johnson & Johnson$869
  • Telix Pharmaceuticals$848
  • Pfizer$750
  • Bayer$498
  • Progenics Pharmaceuticals, Inc.$307
  • plus $3K from 30 others

What the payments were for

  • Travel & lodging$3996%
  • Food & beverage$6,63792%
  • Education$1853%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,221 in reported general payments places this provider in the 95th percentile of 2,888 physician assistant providers in Arizona.

See all physician assistant providers in Arizona

Medicare billing

Part B allowed, 2024
$28,965
Medicare patients
211
Services billed
916

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide25$331,464
Lupron DepotLeuprolide Acetate12$139,020
MyrbetriqMirabegron128$89,759
GemtesaVibegron64$46,124
Tamsulosin Hcl798$13,154
Solifenacin Succinate152$6,447
Estradiol106$6,273
Trospium Chloride96$4,270
Testosterone Cypionate44$2,632
Trimethoprim30$1,985
Oxybutynin Chloride ErOxybutynin Chloride73$1,946
Methenamine Hippurate27$1,915
Potassium Citrate ErPotassium Citrate16$1,383
Cephalexin85$1,274
Alfuzosin Hcl ErAlfuzosin Hcl42$1,144

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$246$421,223153 claims
AbbVieLupron Depot$29$139,02012 claims
Sumitomo Pharma America, Inc.Gemtesa$196$46,12464 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,888 physician assistant providers in Arizona.

Other physician assistant in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →